Cargando…

Risk Factor Assessment of Lymph Node Metastasis in Patients With FIGO Stage IB1 Cervical Cancer

OBJECTIVES: To assess the risk factors of lymph node metastasis (LNM) in patients with FIGO stage (2009) IB1 cervical cancer (CC). METHODS: Patients with FIGO stage IB1 CC who underwent radical resection between 2012 and 2018 were recruited. The risk factors for LNM were analysed. A recursive partit...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Mu, Xie, Xiaoyan, Cai, Liangzhi, Xie, Yongjin, Gao, Qiao, Sun, Pengming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9007329/
https://www.ncbi.nlm.nih.gov/pubmed/35433446
http://dx.doi.org/10.3389/fonc.2022.809159
_version_ 1784686823481540608
author Xu, Mu
Xie, Xiaoyan
Cai, Liangzhi
Xie, Yongjin
Gao, Qiao
Sun, Pengming
author_facet Xu, Mu
Xie, Xiaoyan
Cai, Liangzhi
Xie, Yongjin
Gao, Qiao
Sun, Pengming
author_sort Xu, Mu
collection PubMed
description OBJECTIVES: To assess the risk factors of lymph node metastasis (LNM) in patients with FIGO stage (2009) IB1 cervical cancer (CC). METHODS: Patients with FIGO stage IB1 CC who underwent radical resection between 2012 and 2018 were recruited. The risk factors for LNM were analysed. A recursive partitioning analysis (RPA) was used to divide the patients into risk groups and assess their risk of LNM. RESULTS: The 5-year overall survival rate was 91.72%, while 80.0% and 93.5% for patients with or without LNM (P<0.05). Multivariable logistic regression analysis showed that lymphovascular invasion (LVI), depth of invasion (DI), tumour size (TS), squamous cell carcinoma (SCC) antigen level were independent risk factors (all P<0.05). Patients were divided into low-risk (no LVI, DI <1/2, TS <2 cm), intermediate-risk (no LVI, DI <1/2, TS ≥2 cm; no LVI, DI ≥1/2, normal SCC level; LVI, DI <1/2, TS <2 cm), and high-risk (no LVI, DI ≥1/2, SCC level ≥1.5 ng/ml; LVI, TS <2 cm, DI ≥1/2; LVI, TS ≥2 cm) groups by RPA according to these four factors. The incidence of LNM among the three groups was 0.00%, 4.40%, and 24.10%, respectively (all P<0.001). The 5-year overall survival rates differed among the groups (98.2%, 92.7%, 83.0%, respectively, P=0.001). CONCLUSIONS: LNM affects the prognosis of patients with FIGO stage IB1 CC. Lymphadenectomy may be avoided for patients in the low-risk group and recommended for those in the high-risk group. Whether dissection is performed in the intermediate-risk group depends on the lymph node biopsy results.
format Online
Article
Text
id pubmed-9007329
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90073292022-04-14 Risk Factor Assessment of Lymph Node Metastasis in Patients With FIGO Stage IB1 Cervical Cancer Xu, Mu Xie, Xiaoyan Cai, Liangzhi Xie, Yongjin Gao, Qiao Sun, Pengming Front Oncol Oncology OBJECTIVES: To assess the risk factors of lymph node metastasis (LNM) in patients with FIGO stage (2009) IB1 cervical cancer (CC). METHODS: Patients with FIGO stage IB1 CC who underwent radical resection between 2012 and 2018 were recruited. The risk factors for LNM were analysed. A recursive partitioning analysis (RPA) was used to divide the patients into risk groups and assess their risk of LNM. RESULTS: The 5-year overall survival rate was 91.72%, while 80.0% and 93.5% for patients with or without LNM (P<0.05). Multivariable logistic regression analysis showed that lymphovascular invasion (LVI), depth of invasion (DI), tumour size (TS), squamous cell carcinoma (SCC) antigen level were independent risk factors (all P<0.05). Patients were divided into low-risk (no LVI, DI <1/2, TS <2 cm), intermediate-risk (no LVI, DI <1/2, TS ≥2 cm; no LVI, DI ≥1/2, normal SCC level; LVI, DI <1/2, TS <2 cm), and high-risk (no LVI, DI ≥1/2, SCC level ≥1.5 ng/ml; LVI, TS <2 cm, DI ≥1/2; LVI, TS ≥2 cm) groups by RPA according to these four factors. The incidence of LNM among the three groups was 0.00%, 4.40%, and 24.10%, respectively (all P<0.001). The 5-year overall survival rates differed among the groups (98.2%, 92.7%, 83.0%, respectively, P=0.001). CONCLUSIONS: LNM affects the prognosis of patients with FIGO stage IB1 CC. Lymphadenectomy may be avoided for patients in the low-risk group and recommended for those in the high-risk group. Whether dissection is performed in the intermediate-risk group depends on the lymph node biopsy results. Frontiers Media S.A. 2022-03-30 /pmc/articles/PMC9007329/ /pubmed/35433446 http://dx.doi.org/10.3389/fonc.2022.809159 Text en Copyright © 2022 Xu, Xie, Cai, Xie, Gao and Sun https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Xu, Mu
Xie, Xiaoyan
Cai, Liangzhi
Xie, Yongjin
Gao, Qiao
Sun, Pengming
Risk Factor Assessment of Lymph Node Metastasis in Patients With FIGO Stage IB1 Cervical Cancer
title Risk Factor Assessment of Lymph Node Metastasis in Patients With FIGO Stage IB1 Cervical Cancer
title_full Risk Factor Assessment of Lymph Node Metastasis in Patients With FIGO Stage IB1 Cervical Cancer
title_fullStr Risk Factor Assessment of Lymph Node Metastasis in Patients With FIGO Stage IB1 Cervical Cancer
title_full_unstemmed Risk Factor Assessment of Lymph Node Metastasis in Patients With FIGO Stage IB1 Cervical Cancer
title_short Risk Factor Assessment of Lymph Node Metastasis in Patients With FIGO Stage IB1 Cervical Cancer
title_sort risk factor assessment of lymph node metastasis in patients with figo stage ib1 cervical cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9007329/
https://www.ncbi.nlm.nih.gov/pubmed/35433446
http://dx.doi.org/10.3389/fonc.2022.809159
work_keys_str_mv AT xumu riskfactorassessmentoflymphnodemetastasisinpatientswithfigostageib1cervicalcancer
AT xiexiaoyan riskfactorassessmentoflymphnodemetastasisinpatientswithfigostageib1cervicalcancer
AT cailiangzhi riskfactorassessmentoflymphnodemetastasisinpatientswithfigostageib1cervicalcancer
AT xieyongjin riskfactorassessmentoflymphnodemetastasisinpatientswithfigostageib1cervicalcancer
AT gaoqiao riskfactorassessmentoflymphnodemetastasisinpatientswithfigostageib1cervicalcancer
AT sunpengming riskfactorassessmentoflymphnodemetastasisinpatientswithfigostageib1cervicalcancer